1. Maintenance of Investigators Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
- Author
-
Eichenfield, Lawrence, Stein Gold, Linda, Lynde, Charles, Guenther, Lyn, Greenberger, Shoshana, Chu, Chia-Yu, Ghodsi, Zara, Vlahos, Bonnie, Sanders, Paul, Cha, Amy, and Canosa, Juliana
- Subjects
Adults ,Anti-inflammatory agents ,Atopic dermatitis ,Crisaborole ,Disease control ,Flare ,Investigator’s Static Global Assessment ,Maintenance ,Pediatrics - Abstract
INTRODUCTION: Treatments for atopic dermatitis (AD) often fail to achieve lasting disease control. In the CrisADe CONTROL phase III study (ClinicalTrials.gov: NCT04040192), participants aged ≥ 3 months with mild to moderate AD treated with once-daily (QD) crisaborole, following initial treatment success with crisaborole twice daily (BID), had longer periods of flare-free maintenance, a higher number of flare-free days, and a lower number of flares compared with those who received vehicle. The study was an exploratory analysis of data on the maintenance of response per Investigators Static Global Assessment (ISGA; ISGA score of 0 [clear] or 1 [almost clear]) during the CrisADe CONTROL study through week 52. METHODS: Exploratory endpoints were the time to ISGA response during the open-label run-in period, and the maintenance of ISGA response and the severity and duration of flares during the double-blind maintenance period. Outcomes were stratified by age (participants aged 3 months to
- Published
- 2024